FY2020 EPS Estimates for Catalyst Pharmaceuticals, Inc. Lowered by Analyst (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Research analysts at SunTrust Banks lowered their FY2020 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings of $0.01 per share for the year, down from their previous forecast of $0.05. SunTrust Banks currently has a “Buy” rating and a $5.00 target price on the stock. SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ FY2021 earnings at $0.51 EPS.

ILLEGAL ACTIVITY WARNING: “FY2020 EPS Estimates for Catalyst Pharmaceuticals, Inc. Lowered by Analyst (CPRX)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/13/fy2020-eps-estimates-for-catalyst-pharmaceuticals-inc-lowered-by-analyst-cprx.html.

Several other analysts have also recently weighed in on CPRX. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Finally, Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $5.50.

Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded down $0.12 during midday trading on Monday, reaching $2.87. The company’s stock had a trading volume of 2,011,700 shares, compared to its average volume of 872,389. Catalyst Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.24.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Catalyst Pharmaceuticals by 11.3% during the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock worth $9,242,000 after purchasing an additional 340,614 shares during the period. JPMorgan Chase & Co. raised its position in Catalyst Pharmaceuticals by 1,833.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock valued at $4,240,000 after buying an additional 1,456,830 shares during the last quarter. State Street Corp raised its position in Catalyst Pharmaceuticals by 1,971.1% in the 2nd quarter. State Street Corp now owns 938,195 shares of the biopharmaceutical company’s stock valued at $2,590,000 after buying an additional 892,895 shares during the last quarter. Kennedy Capital Management Inc. raised its position in Catalyst Pharmaceuticals by 298.5% in the 2nd quarter. Kennedy Capital Management Inc. now owns 918,438 shares of the biopharmaceutical company’s stock valued at $2,535,000 after buying an additional 687,938 shares during the last quarter. Finally, Northern Trust Corp raised its position in Catalyst Pharmaceuticals by 620.9% in the 2nd quarter. Northern Trust Corp now owns 802,566 shares of the biopharmaceutical company’s stock valued at $2,215,000 after buying an additional 691,238 shares during the last quarter. 40.19% of the stock is currently owned by institutional investors.

In other news, insider Patrick J. Mcenany bought 20,000 shares of the stock in a transaction dated Tuesday, September 5th. The shares were bought at an average cost of $2.58 per share, with a total value of $51,600.00. Following the completion of the transaction, the insider now directly owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.79% of the stock is owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply